checkAd

     108  0 Kommentare Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 - Seite 3

    Lesen Sie auch


    The Enanta Pharmaceuticals Stock at the time of publication of the news with a fall of -0,47 % to 42,40EUR on Tradegate stock exchange (08. November 2022, 22:26 Uhr).

    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 - Seite 3 Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the initiation of SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 …